PRJNA517451
Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin
In this study we tested 60 epigenetic inhibitors on four DLBCL cell lines to invesitage whether epigenetic reprogramming can induce sensitization towards rituximab and doxorubicin. The exome and transcriptome data uploaded here were then generated to investigate the mechanisms behind the epigenetic reprogramming leading to sensitization.